Another phase II study reported by Kenji Tamura showed that the ORR of nivolumab in advanced cervical cancer patients with PD-L1-positive tumors was 33% (80% CI: 17%–53%) (57).Based on the results of the above studies, the NCCN guidelines recommended pembrolizumab as a second-line regimen indicated for recurrent PD-L1-positive or MSI-H/dMMR cervical cancer in 2020 (71) and added nivolumab as the second-line therapy for PD-L1-positive cervical cancer in 2022 (5). This evidence concerns the gene CD274 and cervical cancer.